CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR
Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical composit...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | WIRTH, David, D PURRO, Norbert GOLDMAN, Erick SMYTH, Mark |
| description | Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_ZA202105175B</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>ZA202105175B</sourcerecordid><originalsourceid>FETCH-epo_espacenet_ZA202105175B3</originalsourceid><addsrcrecordid>eNrjZLB0DooMDnH08fH0c1Vw8w_yDVbwd1NwVHAKCg3x91MPVgiJDPIPBkl6e_o5BrsqePp5eDp5hvgH8TCwpiXmFKfyQmluBkU31xBnD93Ugvz41OKCxOTUvNSS-ChHIwMjQwNTQ3NTJ2Ni1AAAmzMo3w</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR</title><source>esp@cenet</source><creator>WIRTH, David, D ; PURRO, Norbert ; GOLDMAN, Erick ; SMYTH, Mark</creator><creatorcontrib>WIRTH, David, D ; PURRO, Norbert ; GOLDMAN, Erick ; SMYTH, Mark</creatorcontrib><description>Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.</description><language>eng</language><creationdate>2022</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220727&DB=EPODOC&CC=ZA&NR=202105175B$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,309,782,887,25571,76555</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220727&DB=EPODOC&CC=ZA&NR=202105175B$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>WIRTH, David, D</creatorcontrib><creatorcontrib>PURRO, Norbert</creatorcontrib><creatorcontrib>GOLDMAN, Erick</creatorcontrib><creatorcontrib>SMYTH, Mark</creatorcontrib><title>CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR</title><description>Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.</description><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2022</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZLB0DooMDnH08fH0c1Vw8w_yDVbwd1NwVHAKCg3x91MPVgiJDPIPBkl6e_o5BrsqePp5eDp5hvgH8TCwpiXmFKfyQmluBkU31xBnD93Ugvz41OKCxOTUvNSS-ChHIwMjQwNTQ3NTJ2Ni1AAAmzMo3w</recordid><startdate>20220727</startdate><enddate>20220727</enddate><creator>WIRTH, David, D</creator><creator>PURRO, Norbert</creator><creator>GOLDMAN, Erick</creator><creator>SMYTH, Mark</creator><scope>EVB</scope></search><sort><creationdate>20220727</creationdate><title>CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR</title><author>WIRTH, David, D ; PURRO, Norbert ; GOLDMAN, Erick ; SMYTH, Mark</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_ZA202105175B3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2022</creationdate><toplevel>online_resources</toplevel><creatorcontrib>WIRTH, David, D</creatorcontrib><creatorcontrib>PURRO, Norbert</creatorcontrib><creatorcontrib>GOLDMAN, Erick</creatorcontrib><creatorcontrib>SMYTH, Mark</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>WIRTH, David, D</au><au>PURRO, Norbert</au><au>GOLDMAN, Erick</au><au>SMYTH, Mark</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR</title><date>2022-07-27</date><risdate>2022</risdate><abstract>Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng |
| recordid | cdi_epo_espacenet_ZA202105175B |
| source | esp@cenet |
| title | CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T08%3A02%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=WIRTH,%20David,%20D&rft.date=2022-07-27&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EZA202105175B%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |